In addition to 5-aza-dC, another somewhat less effective DNMT1 inhibitor, 5-azacytidine (5-aza-C), has been shown to partially reactivate the FMR1 gene in NPCs derived from FXS iPSCs [111,112] and in vitro differentiated neurons [111]. The gene discussed is DNMT1; the disease is fragile X syndrome.